MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 130292 | Name: Treprostinil palmitil
Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Treprostinil palmitil is the prodrug of treprostinil (TRE), having an extended duration of activity with reduced side effects as compared to TRE. The powdered version of Treprostinil palmitil, which is inhaled, has been found to increase anti-inflammatory and antifibrotic activity in rodents modelling asthma and pulmonary fibrosis. The powdered form is undergoing clinical trials.

Chemical Structure

Treprostinil palmitil
Treprostinil palmitil
CAS#1706528-83-7

Theoretical Analysis

MedKoo Cat#: 130292

Name: Treprostinil palmitil

CAS#: 1706528-83-7

Chemical Formula: C39H66O5

Exact Mass: 614.4910

Molecular Weight: 614.95

Elemental Analysis: C, 76.17; H, 10.82; O, 13.01

Price and Availability

Size Price Availability Quantity
5mg USD 515.00 2 Weeks
10mg USD 900.00 2 Weeks
Bulk Inquiry
Buy Now
Add to Cart
Related CAS #
No Data
Synonym
Treprostinil palmitil; INS1009; INS 1009; INS-1009
IUPAC/Chemical Name
hexadecyl 2-(((1R,2R,3aS,9aS)-2-hydroxy-1-((S)-3-hydroxyoctyl)-2,3,3a,4,9,9a-hexahydro-1H-cyclopenta[b]naphthalen-5-yl)oxy)acetate
InChi Key
XOKCXRVJBBLBSX-HDMCCQRMSA-N
InChi Code
InChI=1S/C39H66O5/c1-3-5-7-8-9-10-11-12-13-14-15-16-17-19-26-43-39(42)30-44-38-23-20-21-31-27-35-32(28-36(31)38)29-37(41)34(35)25-24-33(40)22-18-6-4-2/h20-21,23,32-35,37,40-41H,3-19,22,24-30H2,1-2H3/t32-,33-,34+,35-,37+/m0/s1
SMILES Code
O=C(OCCCCCCCCCCCCCCCC)COC1=C2C[C@]3([H])[C@]([C@@H](CC[C@@H](O)CCCCC)[C@H](O)C3)([H])CC2=CC=C1
Appearance
To be determined
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
To be determined
Shelf Life
>2 years if stored properly
Drug Formulation
To be determined
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 614.95 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1. : Chapman RW, Li Z, Chun D, Gauani H, Malinin V, Plaunt AJ, Cipolla D, Perkins WR, Corboz MR. Treprostinil palmitil, an inhaled long-acting pulmonary vasodilator, does not show tachyphylaxis with daily dosing in rats. Pulm Pharmacol Ther. 2021 Feb;66:101983. doi: 10.1016/j.pupt.2020.101983. Epub 2020 Dec 17. PMID: 33346142. 2: Corboz MR, Plaunt AJ, Malinin V, Li Z, Gauani H, Chun D, Cipolla D, Perkins WR, Chapman RW. Treprostinil palmitil inhibits the hemodynamic and histopathological changes in the pulmonary vasculature and heart in an animal model of pulmonary arterial hypertension. Eur J Pharmacol. 2022 Feb 5;916:174484. doi: 10.1016/j.ejphar.2021.174484. Epub 2021 Sep 9. PMID: 34508752. 3: Chapman RW, Corboz MR, Fernandez C, Sullivan E, Stautberg A, Plaunt AJ, Konicek DM, Malinin V, Li Z, Cipolla D, Perkins W. Characterisation of cough evoked by inhaled treprostinil and treprostinil palmitil. ERJ Open Res. 2021 Feb 15;7(1):00592-2020. doi: 10.1183/23120541.00592-2020. PMID: 33614774; PMCID: PMC7882781. 4: Corboz MR, Plaunt AJ, Malinin VS, Li Z, Gauani H, Chun D, Cipolla D, Perkins WR, Chapman RW. Assessment of Inhaled Treprostinil Palmitil, Inhaled and Intravenous Treprostinil, and Oral Selexipag in a Sugen/Hypoxia Rat Model of Pulmonary Arterial Hypertension. J Pharmacol Exp Ther. 2022 Oct;383(1):103-116. doi: 10.1124/jpet.122.001174. Epub 2022 Aug 31. PMID: 36507843. 5: Plaunt AJ, Islam S, Macaluso T, Gauani H, Baker T, Chun D, Viramontes V, Chang C, Corboz MR, Chapman RW, Li Z, Cipolla DC, Perkins WR, Malinin VS. Development and Characterization of Treprostinil Palmitil Inhalation Aerosol for the Investigational Treatment of Pulmonary Arterial Hypertension. Int J Mol Sci. 2021 Jan 7;22(2):548. doi: 10.3390/ijms22020548. PMID: 33430435; PMCID: PMC7828008. 6: Ismat FA, Usansky HH, Villa R, Zou J, Teper A. Safety, Tolerability, and Pharmacokinetics of Treprostinil Palmitil Inhalation Powder for Pulmonary Hypertension: A Phase 1, Randomized, Double-Blind, Single- and Multiple-Dose Study. Adv Ther. 2022 Nov;39(11):5144-5157. doi: 10.1007/s12325-022-02296-x. Epub 2022 Sep 7. PMID: 36070132; PMCID: PMC9525339. 7: Chapman RW, Corboz MR, Malinin VS, Plaunt AJ, Konicek DM, Li Z, Perkins WR. An overview of the biology of a long-acting inhaled treprostinil prodrug. Pulm Pharmacol Ther. 2020 Dec;65:102002. doi: 10.1016/j.pupt.2021.102002. Epub 2021 Feb 15. PMID: 33596473. 8: Croasdell G. European Society of Cardiology (ESC) Congress 2021 (August 27-30, 2021 - Virtual Meeting). Drugs Today (Barc). 2021 Oct;57(10):639-643. doi: 10.1358/dot.2021.57.10.3365971. PMID: 34713872.